Last reviewed · How we verify
Tailored antithrombotic strategy — Competitive Intelligence Brief
marketed
Cardiovascular
Small molecule
Live · refreshed every 30 min
Target snapshot
Tailored antithrombotic strategy (Tailored antithrombotic strategy) — Duk-Woo Park, MD. A personalized anticoagulation approach that tailors antithrombotic therapy selection and dosing based on individual patient characteristics, biomarkers, and clinical risk factors.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Tailored antithrombotic strategy TARGET | Tailored antithrombotic strategy | Duk-Woo Park, MD | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Tailored antithrombotic strategy CI watch — RSS
- Tailored antithrombotic strategy CI watch — Atom
- Tailored antithrombotic strategy CI watch — JSON
- Tailored antithrombotic strategy alone — RSS
Cite this brief
Drug Landscape (2026). Tailored antithrombotic strategy — Competitive Intelligence Brief. https://druglandscape.com/ci/tailored-antithrombotic-strategy. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing